Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

With $3B fund, Arch seeks long-term alignment with LPs, start-ups

Veteran firm aiming to invest biggest-ever Fund XII in companies with high-impact, transformational goals

June 30, 2022 2:00 AM UTC

Arch will invest nearly $3 billion from its twelfth venture fund to build ambitious biotech start-ups, continuing a decades-long strategy of creating companies that intend to make broad and deep impacts on science and medicine.

The firm announced its $2.975 billion Fund XII less than 18 months after its $1.9 billion predecessor, from which Arch Venture Partners has made several large commitments to companies built from scratch...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Arch Venture Partners